

CAPSULE COMMENTARIES

Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 Diabetes

François R. Jornayvaz, M.D.

Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospitals, Geneva, Switzerland.

J Gen Intern Med 29(2):356

DOI: 10.1007/s11606-013-2676-x

© Society of General Internal Medicine 2013

This study by Patrick et al.¹ investigated the pattern of insulin initiation, as well as treatment intensification, among patients with type 2 diabetes compared to American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines. Although this observational study may not be representative of the general population, as the 7,932 studied patients were derived from a single commercial insurance company from a single state, the reported data are relevant to the treatment of type 2 diabetes for both primary care physicians and specialists.

The main finding was that insulin was frequently initiated without the withdrawal of sulfonylureas or meglitinides, as recommended by the guidelines. Moreover, sulfonylureas were started in 29 % and meglitinides in 11 % of patients following insulin initiation. This is concerning, given the important risk of hypoglycemia when combining these antidiabetic agents. Furthermore, insulin and hypoglycemic agents represent, respectively, the number two and number four causes of emergency hospitalizations in older Americans,² and hypoglycemia was thought to be the cause of excess death in the ACCORD trial.³

Only one-third of patients benefitted from treatment intensification after insulin initiation, suggesting suboptimal care. However, HbA1c levels were not available. Finally, a quarter of patients discontinued insulin following initiation. This might reflect either poor compliance, possibly due to lack of knowledge or side effects, or the transient need for insulin, such as during steroid use or severe illness.

It is uncertain whether endocrinologists would do better; in this study, only 17 % of patients were seen by

specialists,¹ though there is data that endocrinologists are more likely to intensify diabetes treatment and initiate insulin in type 2 diabetic patients.⁴ This study suggests that a significant portion of type 2 diabetics being initiated on insulin are continued on hypoglycemic agents, notably sulfonylureas and meglitinides, a potentially hazardous practice and in discordance with ADA/EASD guidelines.⁵ Whether this reflects under-appreciation of the hazards of hypoglycemia, inadequate training and knowledge, or some other factor is unknown and deserving of further research.

Conflict of Interest: The author declares that he does not have a conflict of interest.

Corresponding Author: François R. Jornayvaz, M.D.: Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4 1211, Geneva, Switzerland (e-mail: francois.jornayvaz@hcuge.ch).

REFERENCES

1. Patrick AR, Fischer MA, Choudhry NK, Shrank WH, Seeger JD, Liu J, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. *J Gen Intern Med*. doi:10.1007/s11606-013-2643-6.
2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. *New Engl J Med*. 2011;365(21):2002–12. doi:10.1056/NEJMsa1103053.
3. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. *New Engl J Med*. 2008;358(24):2545–59. doi:10.1056/NEJMoa0802743.
4. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? *Diabetes Care*. 2005;28(3):600–6.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2012;35(6):1364–79. doi:10.2337/dc12-0413.